[HTML][HTML] Dynamic monitoring of circulating tumor DNA reveals outcomes and genomic alterations in patients with relapsed or refractory large B-cell lymphoma …
H Zou, W Liu, X Wang, Y Wang, C Wang… - … for Immunotherapy of …, 2024 - ncbi.nlm.nih.gov
Background Over 50% of patients with relapsed or refractory large B-cell lymphoma (r/r
LBCL) receiving CD19-targeted chimeric antigen receptor (CAR19) T-cell therapy fail to …
LBCL) receiving CD19-targeted chimeric antigen receptor (CAR19) T-cell therapy fail to …
Next generation sequencing analysis of fibrin-associated large B-cell lymphoma reveals pathogenic single nucleotide variants
J Do, LN Yenwongfai, SI Do, K Na - Anticancer research, 2024 - ar.iiarjournals.org
Background/Aim: Fibrin-associated large B-cell lymphoma (FA-LBCL) is a newly identified
subtype of Epstein-Barr virus (EBV)-associated lymphoma. Arising within fibrinous material …
subtype of Epstein-Barr virus (EBV)-associated lymphoma. Arising within fibrinous material …
Labile CD22 and CD19 expression in a case of Philadelphia chromosome-like acute lymphoblastic leukemia
J Mukae, D Sadato, T Toya, S Watanabe… - Leukemia & …, 2022 - Taylor & Francis
Blinatumomab, a bispecific T cell engager antibody against CD19/CD3, and inotuzumab
ozogamicin (InO), an anti-CD22 antibody conjugated to calicheamicin, showed significant …
ozogamicin (InO), an anti-CD22 antibody conjugated to calicheamicin, showed significant …